Genomic Health Inc. (NASDAQ:GHDX)’s share price shot up 2.6% during trading on Thursday . The stock traded as high as $28.92 and last traded at $28.64, with a volume of 68,468 shares trading hands. The stock had previously closed at $27.92.

Several brokerages have recently commented on GHDX. Canaccord Genuity upgraded Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Wednesday, June 1st. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Finally, Leerink Swann restated a “buy” rating on shares of Genomic Health in a research note on Thursday, May 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $33.50.

The company’s market cap is $931.02 million. The stock’s 50-day moving average is $26.75 and its 200-day moving average is $27.01.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Wednesday, May 4th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.05. During the same period last year, the company earned ($0.30) EPS. The business earned $80.89 million during the quarter, compared to analyst estimates of $78.12 million. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Equities research analysts expect that Genomic Health Inc. will post ($0.45) EPS for the current fiscal year.

In other news, insider Phillip G. Febbo sold 6,324 shares of the company’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $27.20, for a total value of $172,012.80. Following the transaction, the insider now owns 15,113 shares of the company’s stock, valued at approximately $411,073.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steven Shak sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $25.43, for a total value of $254,300.00. Following the completion of the transaction, the insider now directly owns 336,383 shares in the company, valued at approximately $8,554,219.69. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in GHDX. ProShare Advisors LLC raised its position in shares of Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock valued at $1,012,000 after buying an additional 2,287 shares during the period. EAM Investors LLC acquired a new position in shares of Genomic Health during the fourth quarter valued at approximately $1,055,000. California State Teachers Retirement System raised its position in shares of Genomic Health by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 32,989 shares of the company’s stock valued at $1,161,000 after buying an additional 600 shares during the period. Royce & Associates LLC raised its position in shares of Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock valued at $2,341,000 after buying an additional 31,500 shares during the period. Finally, Russell Frank Co raised its position in shares of Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock valued at $3,517,000 after buying an additional 76,416 shares during the period.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.